| Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults (NCT05422365) | Biopharma Plasma LLC | 2022-07-26 |
| Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP) (NCT05371743) | Sohag University | 2022-05-01 |
| Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients (NCT05311930) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-05-01 |
| An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA (NCT05333861) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-05-01 |
| A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia (NCT05232149) | Beijing InnoCare Pharma Tech Co., Ltd. | 2022-02-21 |
| Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia (NCT05070845) | Pfizer | 2022-02-02 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (NCT04812925) | argenx | 2021-11-17 |
| Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP) (NCT04949009) | Shandong University | 2021-03-01 |
| A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (NCT04596995) | UCB Biopharma SRL | 2021-01-06 |
| A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (NCT04687072) | argenx | 2020-12-16 |
| A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia (NCT04278924) | Takeda | 2020-11-09 |
| A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (NCT04224688) | UCB Biopharma SRL | 2020-06-03 |
| A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (NCT04225156) | argenx | 2020-06-02 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) (NCT04200456) | UCB Biopharma SRL | 2020-01-31 |
| A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (NCT04188379) | argenx | 2019-12-16 |
| Effect of DNMT SNPs on DNA Methylation in Primary ITP (NCT04100876) | Assiut University | 2019-12-01 |
| Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia (NCT05621330) | Qilu Pharmaceutical Co., Ltd. | 2019-10-18 |
| Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine (NCT05551624) | Hospital Civil de Guadalajara | 2018-07-04 |
| A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 (NCT03275740) | Pfizer | 2017-07-17 |
| A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP (NCT03102593) | argenx | 2017-03-13 |
| Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia (NCT01727232) | Henri Mondor University Hospital | 2007-01-01 |
| Managed Access Programs for VAY736, Ianalumab (NCT07244289) | Novartis Pharmaceuticals | |